Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide
followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well
tolerated.
This study will attempt to determine the maximum tolerated dose of the immune therapy
(gemtuzumab) when given in combination with the myeloablative (high dose) drugs used in this
study for allogeneic stem cell transplant. (Part A)